SCHEMBL4285326

SCHEMBL4285326

c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)cn2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 12/20 0.67
ROCK2 O75116 11/20 0.67
AURKB Q96GD4 10/20 0.67
PIM1 P11309 7/20 0.67
CDK5 Q00535 5/20 0.67
DYRK1A Q13627 5/20 0.67
PRKACA P17612 5/20 0.67
CDK2 P24941 5/20 0.67
JAK2 O60674 4/20 0.67
AURKA O14965 4/20 0.67
CDK1 P06493 4/20 0.67
MARK3 P27448 4/20 0.67
MAPK1 P28482 4/20 0.67
GSK3A P49840 4/20 0.67
ROCK1 Q13464 4/20 0.67
CDC42BPA Q5VT25 4/20 0.67
PRKCG P05129 3/20 0.67
AKT1 P31749 3/20 0.67
PRKCD Q05655 3/20 0.67
PRKAA1 Q13131 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29930911 0.82 L3MBTL1 (0.58) GSK3BROCK2AURKBPIM1CDK5
SCHEMBL3666012 0.80 ROCK2 (1.00) GSK3BROCK2AURKBPIM1CDK5
SCHEMBL4287714 0.79 CDC7 (0.67) GSK3BROCK2AURKBPIM1CDK5
SCHEMBL2455100 0.75 GSK3B (1.00) GSK3BROCK2AURKBPIM1CDK5
SCHEMBL3673729 0.74 CDC7 (1.00) GSK3BROCK2AURKBPIM1CDK5
SCHEMBL22558731 0.74 L3MBTL1 (0.71) L3MBTL1DYRK1BPIK3CDPIK3CAPIK3CB
SCHEMBL16014174 0.74 GSK3B (0.57) GSK3BROCK2AURKBPIM1CDK5
SCHEMBL19537482 0.72 L3MBTL1 (0.69) L3MBTL1PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL12838034 0.72 AKT1 (0.53) GSK3BROCK2AURKBPIM1CDK5
SCHEMBL1519534 0.72 AKT1 (0.53) GSK3BROCK2AURKBPIM1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 GSK3B 1/4885ROCK2 48/4885AURKB 125/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 GSK3B 1/4885ROCK2 48/4885AURKB 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.